Friedreich's ataxia pharma - Ataxia UK

Friedreich’s ataxia pharma

Lexeo Therapeutics provides updates on their gene therapy programme for Friedreich’s ataxia cardiomyopathy

On March 24th 2025, the pharmaceutical company Lexeo Therapeutics provided a number of updates on their phase 1/2 trial of the gene therapy drug LX2006 for Friedreich’s ataxia (FA) cardiomyopathy.  […]

Lexeo Therapeutics provides updates on their gene therapy programme for Friedreich’s ataxia cardiomyopathy Read More »

Lexeo announces positive results from their phase 1/2 clinical trial programme for FA cardiomyopathy

Lexeo Therapeutics is a pharmaceutical company developing a gene therapy called LX2006 for people with Friedreich’s ataxia (FA) hypertrophic cardiomyopathy (disease of the heart involving stretching, thickening, or stiffening of

Lexeo announces positive results from their phase 1/2 clinical trial programme for FA cardiomyopathy Read More »

Alterity Therapeutics presents data on the potential of ATH434 to treat FA

The biotechnology company Alterity Therapeutics presented data from their lead Friedreich’s ataxia (FA) drug candidate ATH434 at the 2024 US World Orphan Drug Congress.  In FA, a genetic change in

Alterity Therapeutics presents data on the potential of ATH434 to treat FA Read More »

Voyager Therapeutics and Neurocrine Biosciences announce selection of a lead gene therapy candidate for their FA program

On 26th February, the biotechnology company Voyager Therapeutics announced that as part of their collaboration with the biopharmaceutical company Neurocrine Biosciences, they have selected a lead development candidate in their

Voyager Therapeutics and Neurocrine Biosciences announce selection of a lead gene therapy candidate for their FA program Read More »

Scroll to Top